Phaseline

Targets › CHRNA1

CHRNA1 (Acetylcholine receptor subunit alpha): drug programs, companies and trials

6 programs from 5 companies in 13 trials: 5 Phase 4, 5 Phase 2, 3 Phase 1; Other, Oncology, Respiratory; next expected readout Dec 2026.

[Isoform 1]: Upon acetylcholine binding, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane..; FUNCTION: [Isoform 2]: Non functional acetylcholine receptor alpha subunit which is not integrated into functional acetylcholine-gated cation-selective channels. (UniProt, P02708)

Open in Phaseline: the race on CHRNA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The University of Texas Health Science Center, HoustonALA 10% gel
Muscle-type nicotinic acetylcholine receptor antagonist
HCRTR2, HCRTR1, CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE, HTR2A, PTGS2, PTGS1Phase 4Anesthesia; Cleft Lip and Palate; Pancreatic Ductal Adenocarcinoma (PDAC); Stimulant Use Disorder …Dec 2026
The University of Texas Medical Branch, GalvestonRocuronium
Muscle-type nicotinic acetylcholine receptor antagonist
CHRNA1, CHRNG, CHRNB1, CHRND, CHRNEPhase 4Post Operative Pulmonary ComplicationsDec 2026
Nordsjaellands HospitalRocuronium
Muscle-type nicotinic acetylcholine receptor antagonist
CHRNA1, CHRNG, CHRNB1, CHRND, CHRNEPhase 4Tracheal IntubationApr 2027
The University of Texas Health Science Center, HoustonSuxamethonium
Muscle-type nicotinic acetylcholine receptor agonist
CHRNA1, CHRNG, CHRNB1, CHRND, CHRNEPhase 4Anesthesia–
Memorial Sloan Kettering Cancer CenterRocuronium
Muscle-type nicotinic acetylcholine receptor antagonist
CHRNA1, CHRNG, CHRNB1, CHRND, CHRNEPhase 2Prostate CancerJan 2027
COUR Pharmaceutical Development CompanyCNP-106
Antigenic AChR peptide pool (AChRα and AChRε peptides) delivered in PLGA polymer particles
CHRNA1, CHRNEPhase 1Myasthenia Gravis–

Conditions

Anesthesia (2) Post Operative Pulmonary Complications (1) Prostate Cancer (1) Myasthenia Gravis (1) Tracheal Intubation (1) Cleft Lip and Palate (1) Pancreatic Ductal Adenocarcinoma (PDAC) (1) Stimulant Use Disorder (1) Bipolar II Disorder (1) Bronchopulmonary Dysplasia (1) Onychomycosis of Toenail (1) Neuropsychiatric Syndromes (1)

Modalities

small molecule (6)

Companies

The University of Texas Health Science Center, Houston (2) The University of Texas Medical Branch, Galveston (1) Memorial Sloan Kettering Cancer Center (1) COUR Pharmaceutical Development Company (1) Nordsjaellands Hospital (1)

Related targets

CHRNE (6) CHRNG (5) CHRNB1 (5) CHRND (5) HCRTR2 (1) HCRTR1 (1) HTR2A (1) PTGS2 (1) PTGS1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.